What's behind GSK's latest 2.3% stock surge?

Traders Union
All News
Stocks
GSK surges 2.29% today after Q3 results

Highlights

GSK stock gained 5% in third-quarter 2026 sales to £8.9 billion on strength in specialty medicines and new launches.
Operating profit dropped 16% to £2.13 billion due to Accelerate Growth restructuring, while the company held 2026 earnings guidance steady at 7 to 9%.
Shares are above short- and medium-term averages with firm buying interest, but the long-term trend remains bearish and the next five-day range is forecast at GBX1,784 to GBX1,926.

Sales growth and cash lift offset profit drop on restructuring costs

GSK plc reported third-quarter 2026 results, registering 5% year-on-year sales growth at constant exchange rates to £8.9 billion, mainly attributed to specialty medicines and new launches in respiratory disease and oncology. The company maintained its 2026 core earnings per share growth guidance at 7–9% and declared a third-quarter dividend of 17 pence per share, targeting 70 pence for the full year. Operating profit decreased 16% to £2.13 billion due to a restructuring charge related to its Accelerate Growth program, while vaccine sales fell by 2% and free cash flow increased by £1.8 billion year-to-date after recent out-licensing activity and a special dividend from ViiV Healthcare.

Anton Kharitonov, expert at Traders Union, sees underlying risks despite the share price rebound. He notes that GSK's sales growth and dividend stability have attracted short-term buyers, but the 16% drop in operating profit and ongoing restructuring signal deeper challenges. Technical signals are mixed, with momentum readings split and sellers dominating intraday flows. The stock remains below its 200-day moving average, underlining a still-bearish long-term trend. "Investors should be cautious — headline growth masks persistent structural headwinds and momentum may fade quickly if the upside fails to hold."

Viktoras Karapetjanc, expert at Traders Union, views GSK’s steady sales gains and reaffirmed core EPS guidance as reinforcing long-term confidence. He highlights that recent product launches and strategic cash flow improvements underpin a bullish structure, with rising investor demand seen in the latest session. The current setup presents compelling upside as the company continues to target value through innovation and consistent dividends. "Further growth is likely as market appetite strengthens — GSK offers strong opportunities for patient investors seeking robust setups."

Jainam Mehta, market strategist, takes a balanced technical stance on GSK. He observes that price action above short- and medium-term averages suggests potential for a relief rally, but cautions that mixed oscillator signals keep directional conviction low. A clean breakout above GBX1,858 could spark a tactical long trade, while failure to hold GBX1,847 risks a move to GBX1,784. "With volatility high, tactical entries around key levels may offer the best risk-adjusted opportunities this week."

Mixed momentum signals as price tests resistance amid intraday buying

GSK is trading above both its 20-day (GBX1,826) and 50-day (GBX1,847) moving averages, but remains under the 200-day (GBX1,951), indicating positive short- and medium-term momentum, though the long-term trend is still bearish. Immediate resistance stands at GBX1,858, with the 50-day moving average at GBX1,847 acting as near-term support; the Ichimoku Kijun at GBX1,832 lends additional support. Momentum readings present a mixed picture. The Moving Average Convergence Divergence (MACD) signals bullish momentum while the Average Directional Index (ADX) is neutral, and the Relative Strength Index (RSI) is in the lower neutral range at 45.01 with a sell forecast. The Stochastic RSI and Commodity Channel Index (CCI) confirm a neutral stance. Bull/Bear Power (BBP) at -14.08 means sellers currently dominate intraday momentum, with an “oversold” outlook. The stock is up sharply, gaining GBX41.5, or 2.29% with an upside gap of approximately 1.19%. The current price is near session highs, and intraday volatility stands at 1.50%, pointing to firm buying interest as the session progresses. Oscillator signals are split, reflecting uncertainty in the intraday trend despite the positive move.

Earlier, analysts noted that GSK’s medium- and long-term outlook remained weighted to the downside despite intermittent short-term rallies. The latest price action adds nuance to that view, as renewed short- and medium-term momentum introduces near-term trading opportunities, but with downside risks still dominant, the GBX1,847 support level should be closely monitored in the days ahead.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.